

# Phase I pharmacological study of continuous and intermittent chronomodulated capecitabine therapy

Published: 01-04-2014

Last updated: 15-05-2024

To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs) and recommended dose (RD) of continuous and intermittent chronomodulated capecitabine. Secondary study objectives are: To determine plasma pharmacokinetics of capecitabine...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Miscellaneous and site unspecified neoplasms malignant and unspecified
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON40756

### Source

ToetsingOnline

### Brief title

N14CCT

### Condition

- Miscellaneous and site unspecified neoplasms malignant and unspecified

### Synonym

cancer, malignancies

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Antoni van Leeuwenhoek Ziekenhuis

**Source(s) of monetary or material Support:** Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis (NKI-AVL)

## Intervention

**Keyword:** biomarker, capecitabine, chronotherapy, phase 1

## Outcome measures

### Primary outcome

To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs) and recommended dose (RD) of continuous and intermittent chronomodulated capecitabine.

### Secondary outcome

Secondary study parameters/outcomes include the following:

The plasma pharmacokinetics of capecitabine and its metabolites 5-dFCR, 5-dFUR, 5-FU and FBAL;

The inter- and intra-patient variability in plasma pharmacokinetics;

Baseline and circadian dihydropyrimidine dehydrogenase (DPD) activity in peripheral blood mononuclear cells (PBMCs) and in plasma by means of the dihydrouracil (UH<sub>2</sub>) / uracil (U) ratio;

Baseline and circadian thymidylate synthase (TS) activity in PBMCs;

Baseline thymidine phosphorylase (TP) activity in PBMCs;

The description of pharmacokinetic/pharmacodynamic (PK/PD) relationships;

The preliminary antitumor activity of chronomodulated capecitabine;

Associations of polymorphisms in DPYD or TYMS with DPD or TS enzyme activity in PBMCs and clinical response;

Intracellular pharmacokinetics of 5-FU nucleotides in PBMCs.

# Study description

## Background summary

Capecitabine is a widely used oral prodrug of 5-fluorouracil (5-FU). Enzymatical conversion of capecitabine subsequently by carboxyl esterase (CES), cytidine deaminase (CDA) and thymidine phosphorylase (TP) is warranted for the formation of 5-FU. However, the clinical application of capecitabine is limited by treatment failure and poorly predictable severe toxicity (especially diarrhea and palmar-plantar erythrodysesthesia (PPE)). Treatment safety and efficacy may be improved by synchronization capecitabine therapy to the circadian rhythm of the 5-FU degrading enzyme dihydropyrimidine dehydrogenase (DPD) and its drug target thymidylate synthase (TS).

Approximately 80 percent of 5-FU is metabolized by DPD. Earlier studies, including an observational study performed by our research group, showed that DPD activity fluctuates over the twenty-four hours of the day. This so called circadian rhythm of DPD is characterized by low metabolic capacity during day-time and peak metabolic capacity during the night. Nocturnal DPD activity is approximately 60% higher compared to DPD activity in the afternoon. Consequently, metabolism of 5-FU is most likely increased during the night because of high DPD activity. Besides circadian activity of DPD the enzyme thymidylate synthase (TS) also shows circadian activity. The enzyme TS displays trough activity during the night. Exposure to 5-FU when TS activity is low has been associated with improved 5-FU tolerability.

Circadian rhythms of DPD and TS presumably affect capecitabine treatment pharmacokinetics, safety and tolerability. Safety and the maximum tolerated dose (MTD) for Xeloda® have been determined in earlier phase I trials for continuous and intermittent (day 1-14 of a 21-day course) BID treatment schedules with Xeloda®. Major limitations of these studies were that circadian rhythms in 5-FU metabolism and patient tolerability to Xeloda® were not taken into account. Chronomodulated capecitabine therapy, indicating that capecitabine therapy is synchronized to circadian rhythms of DPD and TS, might be advantageous for Xeloda® BID treatment.

Therefore, we aim to determine the feasibility of chronomodulated capecitabine in a pharmacological phase I clinical study. A new capecitabine dosing schedule is developed by population modeling of capecitabine pharmacokinetics and DPD activity. Capecitabine will be administered continuously on day 1-21 (arm A) and intermittently on day 1-14 (arm B) of 21-day BID dosing schedules. For both study arms, the morning will be administered at 9:00 hours (h) and the late evening dose at 24:00 h. Chronomodulation will be obtained by using a relatively high evening dose of capecitabine.

## Study objective

To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs)

and recommended dose (RD) of continuous and intermittent chronomodulated capecitabine.

Secondary study objectives are:

To determine plasma pharmacokinetics of capecitabine and its metabolites

5-dFCR, 5-dFUR, 5-FU and FBAL;

To determine the inter- and intra-patient variability in plasma pharmacokinetics;

To determine baseline and circadian dihydropyrimidine dehydrogenase (DPD) activity in peripheral blood mononuclear cells (PBMCs) and in plasma by means of the dihydrouracil (UH2) / uracil (U) ratio;

To determine baseline and circadian thymidylate synthase (TS) activity in PBMCs;

To determine baseline thymidine phosphorylase (TP) activity in PBMCs.

To explore pharmacokinetic/pharmacodynamic (PK/PD) relationships;

To investigate the preliminary antitumor activity of chronomodulated capecitabine;

To explore associations of polymorphisms in DPYD or TYMS with DPD or TS enzyme activity in PBMCs and clinical response;

To explore the intracellular pharmacokinetics of 5-FU nucleotides in PBMCs.

## **Study design**

Phase I, single centre, pharmacological, open label, dose-escalation study

## **Study burden and risks**

Participating patients will be hospitalized for two consecutive days in which blood samples will be drawn for pharmacokinetic and pharmacodynamic measurements. Approximately 270 ml blood will be collected plus blood for pharmacogenetics, hematology and serum chemistry. Patients are at risk for capecitabine related adverse effects.

## **Contacts**

### **Public**

Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121  
Amsterdam 1066 CX  
NL

### **Scientific**

Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

1. Histological or cytological proof of cancer
2. Patient who might benefit from treatment with capecitabine, e.g. colon, breast, pancreatic and gastric cancer, ACUP;
3. Age  $\geq 18$  years
4. WHO performance status of 0, 1 or 2;
5. Able and willing to give written informed consent
6. Able and willing to undergo blood sample collection during day-time and during the night for pharmacokinetic (PK) measurements and pharmacodynamic (PD) analysis;
7. Life expectancy  $\geq 3$  months allowing adequate follow up;
8. Minimal acceptable safety laboratory values
  - a. ANC of  $\geq 1.5 \times 10^9 /L$ ;
  - b. Platelet count of  $\geq 100 \times 10^9 /L$ ;
  - c. Hemoglobin  $\geq 6.5$  mmol/L;
  - d. Hepatic function as defined by serum bilirubin  $\leq 1.5 \times \text{ULN}$ , ALAT and ASAT  $\leq 3.0 \times \text{ULN}$  ( $\leq 5 \times \text{ULN}$  in case of liver metastases);
  - e. Renal function as defined by serum creatinine  $\leq 1.5 \times \text{ULN}$  or creatinine clearance  $\geq 60$  ml/min (by Cockcroft-Gault formula).
9. No radio- or chemotherapy within 3 weeks of receiving first dose of study medication (palliative limited radiation for pain reduction is allowed);
10. Able and willing to swallow oral medication;
11. Negative pregnancy test (urine/serum) for female patients with childbearing potential.

## Exclusion criteria

1. Dihydropyrimidine dehydrogenase (DPD) deficiency as assessed on the basis of DPYD IVS14+1G>A (DPYD\*2A) and 2846A>T mutation analysis;
2. Women who are pregnant or breast feeding;
3. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms);
4. Bowel obstructions or motility disorders that may influence the absorption of drugs;
5. Pre-existing neuropathy > grade 1;
6. Unresolved (> grade 1) toxicities (except alopecia) of previous chemotherapy;
7. Patients with known alcoholism, drug addiction and/or psychotic disorders in the history that are not suitable for adequate follow up;
8. The use of any drug or complementary alternative medicine that might interfere with the biotransformation of capecitabine and/or 5FU, like CYP2C9 substrates with narrow therapeutic windows (e.g., vitamin K antagonizing anticoagulants (acenocoumarol, phenprocoumon, warfarin), phenytoin), allopurinol, folic acid, folinic acid, interferon alpha, metronidazol, sorivudine (and analogues). Aluminium hydroxide and magnesium hydroxide can not be administered in the morning and evening/night: the use of aluminium hydroxide and magnesium hydroxide is not an exclusion criterion when administered in the afternoon between 12:00 - 18:00 h;
9. Current participation or previous participation in a study with an investigational compound, or chemo- and/or radiotherapy within 21 days of receiving first dose of study medication. (Palliative limited radiation for pain reduction is allowed);
10. Prior stem cell or bone marrow transplant;
11. Known hypersensitivity to the components of the study drug or its analogs;
12. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;
13. Patients with a known history of hepatitis B or C;
14. Symptomatic cerebral or leptomeningeal metastases;
15. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of capecitabine according to this protocol or puts the patient at high risk for treatment-related complications.

## Study design

## Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

## Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 23-07-2014

Enrollment: 42

Type: Actual

## Medical products/devices used

Product type: Medicine

Brand name: Xeloda

Generic name: capecitabine

Registration: Yes - NL outside intended use

## Ethics review

Approved WMO

Date: 01-04-2014

Application type: First submission

Review commission: METC NedMec

Approved WMO

Date: 20-05-2014

Application type: First submission

Review commission: METC NedMec

Approved WMO

Date: 20-07-2018

Application type: Amendment

Review commission: METC NedMec

Approved WMO

Date: 26-07-2018

Application type: Amendment  
Review commission: METC NedMec

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

ID: 24089

Source: Nationaal Trial Register

Title:

### In other registers

Register	ID
EudraCT	EUCTR2014-000889-22-NL
CCMO	NL48425.031.14
OMON	NL-OMON24089

## Study results

Results posted: 23-11-2020

### First publication

07-05-2020